<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140265" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lacrimal Gland Malignancies</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mueller</surname>
            <given-names>Andrew J.</given-names>
          </name>
          <aff>University of Texas Southwestern Medical School, Dallas, TX</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Czyz</surname>
            <given-names>Craig N.</given-names>
          </name>
          <aff>Ohio University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Mueller declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Craig Czyz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140265.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lacrimal gland masses can arise from many etiologies, including neoplastic and non-neoplastic causes. Of the neoplastic causes, the malignant tumors generally have a poor prognosis and thus are treated aggressively. This usually involves a combination of extensive surgical resection (often orbital exenteration), radiation, and chemotherapy. The most notable exception is orbital lymphoma, which is not treated surgically. Recent developments in treatment strategies involving intra-arterial chemotherapy prior to surgical resection of adenoid cystic carcinoma, the most common malignant epithelial lacrimal gland tumor, may offer a new direction for improving patient outcomes. This activity reviews the evaluation and treatment of malignant lacrimal gland tumors and explains the role of the interprofessional team in managing patients with these conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the presentation and appropriate clinical evaluation for a patient with a suspected malignant lacrimal fossa mass.</p></list-item><list-item><p>Review the malignant causes of lacrimal gland tumors.</p></list-item><list-item><p>Identify factors of the history, physical, or imaging modalities that guide management and treatment.</p></list-item><list-item><p>Summarize the treatment strategies by the interprofessional team for the various malignant etiologies.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140265&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140265">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140265.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tumors of the lacrimal gland fossa account for about 10% of all biopsied orbital masses.<xref ref-type="bibr" rid="article-140265.r1">[1]</xref> There is a wide variety of etiologies for these masses, including infectious, inflammatory, and neoplastic.<xref ref-type="bibr" rid="article-140265.r1">[1]</xref><xref ref-type="bibr" rid="article-140265.r2">[2]</xref>&#x000a0;Furthermore, neoplastic lesions can either be benign or malignant. This activity will focus on malignant lacrimal gland tumors (broadly called lacrimal gland carcinomas). Since the lacrimal gland fossa is in the anterior superolateral orbit, space-occupying lesions of this area of the orbit typically cause inferior and medial globe displacement.</p>
        <p>Proptosis is not always seen but can be present if the posterior growth of a mass pushes the eye forward. Most malignant lesions grow quicker than benign lesions, averaging less than six months from onset to diagnosis compared to 1&#x000a0;to 2 years for benign lesions.<xref ref-type="bibr" rid="article-140265.r3">[3]</xref>&#x000a0;Malignant lacrimal gland lesions generally carry a poor prognosis; thus, quick and early identification is critical to improving a patient's morbidity and mortality. See <bold>Image.</bold>&#x000a0;Lacrimal Gland Malignancy.&#x000a0;</p>
      </sec>
      <sec id="article-140265.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Tumors of the lacrimal gland are similar to tumors of the salivary glands due to their shared embryologic origins. The type of proliferating cell can organize the types of tumors, and the most common distinction is epithelial versus non-epithelial.<xref ref-type="bibr" rid="article-140265.r4">[4]</xref></p>
        <p>
<bold>Epithelial</bold>
</p>
        <p>Nearly 50% of epithelial tumors of the lacrimal gland are malignant, though this may depend on referral patterns, geographic location, and patient population.<xref ref-type="bibr" rid="article-140265.r1">[1]</xref><xref ref-type="bibr" rid="article-140265.r5">[5]</xref></p>
        <p>Adenoid cystic carcinoma (ACC) is the most common malignant epithelial tumor,&#x000a0;comprising 66% of malignant epithelial tumors.&#x000a0;It commonly presents with globe displacement, proptosis, and ptosis; pain and frontotemporal numbness are more specific symptoms as adenoid cystic carcinoma is classically known for invading orbital nerves.<xref ref-type="bibr" rid="article-140265.r6">[6]</xref></p>
        <p>Carcinoma ex pleomorphic adenoma (CEPA, also known as pleomorphic adenocarcinoma or malignant mixed tumor) is the second most common type of epithelial malignancy and, as the name suggests, transforms from a benign pleomorphic adenoma tumor, either from a previously biopsied or resected tumor (if taken piecemeal or if the capsule was ruptured during removal), or de novo from a primary pleomorphic adenoma without prior surgery.<xref ref-type="bibr" rid="article-140265.r2">[2]</xref><xref ref-type="bibr" rid="article-140265.r7">[7]</xref>&#x000a0;This transformation can occur years or decades after the primary pleomorphic adenoma is treated. The malignant component can be any epithelial cell, but most commonly is adenocarcinoma&#x000a0;not-otherwise-specified or mucoepidermoid carcinoma.&#x000a0;</p>
        <p>Mucoepidermoid carcinoma (MEC) and adenocarcinoma not-otherwise-specified (NOS) are the next most common types. Mucoepidermoid carcinoma is a common salivary gland tumor but a rare lacrimal gland tumor.&#x000a0;Adenocarcinoma NOS is a primary adenocarcinoma of the lacrimal gland that does not have features of the other listed types. Other epithelial malignancies include ductal carcinoma (similar to mammary ductal carcinoma), acinic cell carcinoma, myoepithelial carcinoma, epithelial-myoepithelial carcinoma, cystadenocarcinoma, carcinosarcoma, polymorphous low-grade adenocarcinoma, sebaceous cell carcinoma, squamous cell carcinoma, and basal cell carcinoma.</p>
        <p>
<bold>Lymphoid</bold>
</p>
        <p>The overwhelming majority of lacrimal gland lymphomas are non-Hodgkin's B cell lymphomas. The most common subtype is extranodal marginal zone lymphoma (EMZL, MALT lymphoma) which makes up to 40% of lacrimal gland lymphomas.&#x000a0;It also&#x000a0;may be associated with inflammatory diseases such as reactive (benign) lymphoid hyperplasia, IgG4-related disease, Sjogren syndrome, and&#x000a0;gastric <italic toggle="yes">H. pylori</italic> infection.<xref ref-type="bibr" rid="article-140265.r8">[8]</xref><xref ref-type="bibr" rid="article-140265.r9">[9]</xref>&#x000a0;</p>
        <p>Other subtypes include follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma.&#x000a0;Lymphomas present with painless growth and usually minimal signs of inflammation. Orbital lesions often precede systemic lymphoma presentation, but the disease may be isolated to just the orbit&#x000a0;without every developing systemic disease.</p>
        <p>
<bold>Mesenchymal</bold>
</p>
        <p>Malignant mesenchymal tumors of the lacrimal gland are very rare, with vascular lesions most common.<xref ref-type="bibr" rid="article-140265.r4">[4]</xref></p>
        <p>
<bold>Metastasis</bold>
</p>
        <p>Metastases to the lacrimal gland from systemic cancers are exceedingly rare since there are no lymph nodes in the lacrimal gland.&#x000a0;These cases are described in the literature in isolated case reports, and the most common primary site is the breast.<xref ref-type="bibr" rid="article-140265.r8">[8]</xref><xref ref-type="bibr" rid="article-140265.r10">[10]</xref></p>
      </sec>
      <sec id="article-140265.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In general,&#x000a0;lacrimal gland carcinomas do not show a gender preference, though some exceptions exist.&#x000a0;Adenocarcinoma NOS and ductal carcinoma have a slight predilection for males, whereas MEC and lymphoma have a slight female predilection.<xref ref-type="bibr" rid="article-140265.r11">[11]</xref><xref ref-type="bibr" rid="article-140265.r12">[12]</xref>&#x000a0;</p>
        <p>All types of malignant lesions can&#x000a0;appear at any age, but most are typically found in the older adult age group (6th decade or later).<xref ref-type="bibr" rid="article-140265.r5">[5]</xref>&#x000a0;The notable exception to this is adenoid cystic carcinoma, which has an average age of diagnosis of 40 years. There is no racial or geographic preference for tumors, though this may be because they are rare overall.</p>
      </sec>
      <sec id="article-140265.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Malignant tumors arise from genetic changes involving oncogenes and tumor suppressor genes. Some of these changes have been characterized by specific lacrimal gland neoplasms (see <bold>Image.</bold>&#x000a0;Lacrimal Gland Lymphoma, 25&#x000d7; view). For adenoid cystic carcinoma, abnormalities in MYB or MYB-NFIB protein expression have been identified and may&#x000a0;serve as&#x000a0;a critical event in the oncogenic process (see <bold>Image.</bold> Lacrimal Gland Adenoid Cystic Carcinoma, 25&#x000d7;).&#x000a0;</p>
        <p>Carcinoma ex pleomorphic adenoma tumors likely have the same underlying genetic abnormalities as pleomorphic adenomas, such as PLAG1, and the genetic abnormalities were seen in the corresponding tumor's malignant component (see <bold>Image.</bold> Lacrimal Gland Pleomorphic Adenoma, 25&#x000d7;). Mucoepidermoid carcinoma of the salivary gland&#x000a0;has been shown to harbor a translocation between chromosomes 11 and 19, resulting in a fusion of oncogenes CRTC1 and MAML2, and it has been found that lacrimal gland MEC tumors are similar.<xref ref-type="bibr" rid="article-140265.r13">[13]</xref>&#x000a0;</p>
        <p>Ductal carcinomas frequently exhibit HER2 and androgen receptor positivity and are always ER and PR negative.&#x000a0;For lymphoma,&#x000a0;EMZL exhibits a translocation between chromosomes 14 and 18 or between chromosomes 3 and 14; follicular lymphoma has translocations between chromosomes 14 and 18, and mantle cell lymphoma has translocations between chromosomes 11 and 14.<xref ref-type="bibr" rid="article-140265.r8">[8]</xref></p>
      </sec>
      <sec id="article-140265.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Adenoid cystic carcinoma has multiple histological forms. The most common is the cribriform (Swiss cheese) pattern with nests of myoepithelial and ductal cells with cylindrical cystic structures filled with hyaline basal lamina or basophilic mucoid (glycosaminoglycan) material.<xref ref-type="bibr" rid="article-140265.r3">[3]</xref>&#x000a0;The other forms are tubular and solid, and usually, there is a mix of the different forms within one tumor. The neoplasm is usually unencapsulated and shows infiltration into the surrounding tissue.&#x000a0;Perineural growth is characteristic.</p>
        <p>Carcinoma ex pleomorphic adenoma requires histology of both benign (pleomorphic adenoma precursor) and malignant components, with a transition zone between the two parts.&#x000a0;The malignant component may appear as any of the other malignant epithelial lesions listed above (with adenocarcinoma NOS or MEC being the most common), or it may be undifferentiated.</p>
        <p>Adenocarcinoma NOS exhibits cells with glandular or ductal differentiation but lacks distinctive features of other tumors and cannot be classified further.</p>
        <p>Mucoepidermoid carcinoma has three cell types on examination: epidermoid-squamous cells, mucin-producing cells, and intermediate cells.</p>
        <p>Ductal carcinoma resembles mammary ductal carcinoma and is composed of solid epithelial nests in an infiltrative, lobular, or cribriform arrangement and usually has a high mitotic rate and areas of necrosis.<xref ref-type="bibr" rid="article-140265.r10">[10]</xref><xref ref-type="bibr" rid="article-140265.r14">[14]</xref></p>
        <p>EMZL reveals diffusely-infiltrating small cells with abundant cytoplasm and slightly indented nuclei without nucleoli.&#x000a0;Follicular lymphoma displays a partially follicular growth pattern with closely packed neoplastic cells without mantle zones.&#x000a0;DLBCL manifests as diffusely-growing large B cells with a nucleus twice that of a normal lymphocyte and has many morphologic variants. Mantle cell lymphoma exhibits a monotonous pattern of small to medium lymphocytes with scant cytoplasm, irregular nuclei, and no nucleoli.</p>
      </sec>
      <sec id="article-140265.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Demographic data is essential to collect, including age, gender, ethnicity, and race. Systemic medical history is also vital to ascertain possible etiologies: history of recent illness, history of autoimmune or inflammatory disease, history of cancer or chemotherapy and/or radiation, history of systemic immunosuppression, history of prior trauma or surgery. A comprehensive review of systems may pick up on systemic autoimmune or inflammatory disease associations.</p>
        <p>Obtain a thorough ophthalmologic history regarding blurry vision, double vision, change in outward appearance or facial symmetry, pain, light sensitivity, pain with eye movement, eyelid swelling or redness, discharge, tenderness, tearing, dryness. Consider comparing old photographs to evaluate changes in eye or eyelid position or appearance.</p>
        <p>A complete eye exam by a trained optometrist, ophthalmologist, or oculoplastic and orbital surgeon should be performed. This includes checking visual acuity for decreased vision, pupillary light reflexes for adequate responses and the presence of a relative afferent pupillary defect (rAPD), and other signs of optic neuropathy such as color vision deficits, red light saturation, and visual field defects.</p>
        <p>Evaluating ocular motility can provide the degree of any limitations and the presence and pattern of diplopia. It is also prudent to assess any globe malposition, especially inferiorly and medially for lacrimal gland tumors, and perform exophthalmometry to evaluate proptosis. Digital palpation of the orbit and lacrimal gland may identify masses, and there may be resistance to retropulsion of the globe if a mass is present.</p>
        <p>Palpation of regional lymph nodes can reveal lymphadenopathy. Hypoesthesia of the first or second divisions of the trigeminal nerve should be checked to evaluate for orbital nerve compression or invasion. There may be eyelid edema, erythema, or warmth and a directly visualized enlarged and tender lacrimal gland with secondary upper lid ptosis or S-shaped lid deformity. The conjunctiva may be injected, especially overlying the area of the lacrimal gland. An intraocular exam is also needed to evaluate for signs of uveitis.</p>
      </sec>
      <sec id="article-140265.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>It may be difficult to distinguish between benign and malignant lesions based on clinical evaluation alone.&#x000a0;More rapid onset may hint towards a more aggressive or malignant process. If there was slow progression initially that then became rapid, it could indicate the malignant transformation of a pleomorphic adenoma into a carcinoma ex pleomorphic adenoma. The presence or absence of pain can also help predict the nature of the offending lesion, as the most common malignant lesion, adenoid cystic carcinoma, can exhibit perineural invasion. Usually, orbital imaging is helpful and often necessary to confirm and characterize a possible orbital lesion. Characteristics to discern are whether the tumor is solid vs. cystic, well-defined vs. infiltrative, the presence or absence and amount of calcification, the presence of fat or fluid, bony remodeling or destruction, and contrast enhancement.<xref ref-type="bibr" rid="article-140265.r15">[15]</xref><xref ref-type="bibr" rid="article-140265.r16">[16]</xref>&#x000a0;Extension of a mass posteriorly towards the orbital apex ("wedge sign") is a finding that correlates with concerning disease and the need for biopsy.<xref ref-type="bibr" rid="article-140265.r17">[17]</xref></p>
        <p>Computed tomography (CT) is expedient, widely available, cost-effective, and especially helpful for lacrimal fossa anatomy. It is widely considered the initial imaging modality of choice for lacrimal gland lesions, especially if a benign tumor is suspected.&#x000a0;It can identify the presence and size of a mass and its effects on surrounding structures such as the bone (most importantly), extraocular muscles, and the globe. Contrast administration is also helpful to look for enhancing lesions. Computed tomography scans also readily show calcification within a lesion, which can help differentiate the offending mass.</p>
        <p>Magnetic resonance imaging (MRI) is more expensive, harder to obtain, and has a longer duration but gives superior soft tissue detail. The various image processing sequences allow for detailed characterization of the mass in question, and DWI may delineate benign versus malignant.<xref ref-type="bibr" rid="article-140265.r18">[18]</xref>&#x000a0;</p>
        <p>Unlike CT, MRI has limited bone visualization but&#x000a0;can better evaluate tumor involvement of orbital nerves, important for adenoid cystic carcinoma.<xref ref-type="bibr" rid="article-140265.r16">[16]</xref> Because of this, it&#x000a0;may be a better imaging modality when a malignant lesion is suspected. Many&#x000a0;cases may require both CT and MRI imaging&#x000a0;before further management decisions. See <bold>Image.</bold>&#x000a0;Adenoid&#x000a0;Cystic&#x000a0;Carcinoma.&#x000a0;</p>
      </sec>
      <sec id="article-140265.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of&#x000a0;malignant lacrimal gland tumors has not been clearly established because of their rarity and poor prognosis. Yet, the established goals for treatment are local tumor control and prevention of both local recurrences and distant metastases.<xref ref-type="bibr" rid="article-140265.r19">[19]</xref>&#x000a0;</p>
        <p>The first step in all suspected malignancies is establishing a formal histological diagnosis, usually achieved via incisional biopsy. In some cases, small or easily accessible lesions can be excised entirely. Treatment can then be directed by tumor grading and staging. Historically&#x000a0;the treatment of most lacrimal gland carcinomas&#x000a0;has included orbital exenteration with or without bone removal and adjuvant high dose radiation 4&#x000a0;to 6 weeks after surgery.</p>
        <p>Adenoid cystic carcinoma&#x000a0;has had developments in treatment strategies, though there is still no widespread consensus.&#x000a0;Treatment may involve a combination of tumor removal, radiation therapy, and orbital exenteration with varying survival rates.<xref ref-type="bibr" rid="article-140265.r20">[20]</xref> There has been a push towards globe-sparing surgery due to the functional, cosmetic, and psychologic morbidity of orbital exenterations, with similar survival results.<xref ref-type="bibr" rid="article-140265.r21">[21]</xref><xref ref-type="bibr" rid="article-140265.r22">[22]</xref></p>
        <p>More recently, intra-arterial cytoreductive chemotherapy (IACC) has been used successfully before orbital exenteration and radiation therapy and may be combined with globe-sparing surgery and adjuvant radiation therapy.<xref ref-type="bibr" rid="article-140265.r23">[23]</xref>&#x000a0;Nonetheless, extensive surgery may still be indicated for locally advanced cases but does not prevent metastasis or improve survival.<xref ref-type="bibr" rid="article-140265.r24">[24]</xref>&#x000a0;</p>
        <p>The treatment of carcinoma ex pleomorphic adenoma depends on the&#x000a0;histologic grade and stage at presentation.&#x000a0;An isolated, well-defined mass may be treated with excisional surgery alone without radiation.&#x000a0;On the other hand, ill-defined lesions invading the tumor capsule or surrounding orbital tissue are often treated similar to ACC with&#x000a0;excision, possible orbital exenteration, and adjuvant radiation therapy.<xref ref-type="bibr" rid="article-140265.r25">[25]</xref></p>
        <p>Adenocarcinoma NOS and the other malignant lesions are usually treated similarly to ACC with exenteration and&#x000a0;radiation therapy.&#x000a0;If only a microscopic tumor is present on histopathology, plaque radiation therapy can be considered a treatment option for any lacrimal gland malignancy.<xref ref-type="bibr" rid="article-140265.r26">[26]</xref></p>
        <p>The management of ocular adnexal lymphoma depends on the extent of systemic involvement. First, an incisional biopsy is necessary to establish the diagnosis and ascertain the subtype of lymphoma and its genetic characteristics. This is followed by a systemic workup&#x000a0;by an oncologist, potentially including systemic imaging and/or a bone marrow biopsy. Unlike the other malignancies of the lacrimal gland, definitive treatment of lymphoma is not surgical. If the lymphoma is located in the orbit only, then external beam radiation therapy is the established initial treatment, except for DLBCL and mantle cell lymphoma, which are treated by chemotherapy.<xref ref-type="bibr" rid="article-140265.r18">[18]</xref>&#x000a0;Chemotherapy is indicated if there is systemic involvement, with possible radiation therapy as needed in select cases.</p>
      </sec>
      <sec id="article-140265.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In addition to the malignant lesions above, other etiologies can present as lacrimal gland fossa lesions. Two major categories for these other causes are inflammatory lesions and benign tumors. Altogether, inflammatory lesions make up the most common cause of lacrimal gland enlargement.<xref ref-type="bibr" rid="article-140265.r5">[5]</xref> The single most common etiology is dacryoadenitis, which can be unilateral or bilateral and inflammatory or infectious.</p>
        <p>
<bold>Inflammatory Lesions</bold>
<xref ref-type="bibr" rid="article-140265.r2">[2]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic orbital inflammatory syndrome (IOIS), or orbital pseudotumor</p>
          </list-item>
          <list-item>
            <p>IgG-4 related disease</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Granulomatosis with polyangiitis</p>
          </list-item>
          <list-item>
            <p>Dacryoadenitis</p>
          </list-item>
          <list-item>
            <p>Sjogren syndrome</p>
          </list-item>
          <list-item>
            <p>Thyroid eye disease</p>
          </list-item>
        </list>
        <p>
<bold>Benign Tumors</bold>
<xref ref-type="bibr" rid="article-140265.r4">[4]</xref>
<xref ref-type="bibr" rid="article-140265.r8">[8]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Epithelial
<list list-type="bullet"><list-item><p>Pleomorphic adenoma</p></list-item><list-item><p>Dacryops (lacrimal gland cyst)</p></list-item><list-item><p>Oncocytoma</p></list-item><list-item><p>Myoepithelioma</p></list-item><list-item><p>Cystadenoma</p></list-item><list-item><p>Warthin tumor</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Lymphoproliferative
<list list-type="bullet"><list-item><p>Reactive lymphoid hyperplasia (benign lymphoepithelial lesion)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Mesenchymal
<list list-type="bullet"><list-item><p>Capillary or cavernous hemangioma</p></list-item><list-item><p>Angiolymphoid hyperplasia with eosinophilia</p></list-item><list-item><p>Granular cell tumor</p></list-item><list-item><p>Fibrous histiocytoma</p></list-item><list-item><p>A solitary fibrous tumor (hemangiopericytoma)</p></list-item><list-item><p>Neurofibroma</p></list-item><list-item><p>Schwannoma</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Some&#x000a0;lesions can be found near the&#x000a0;superolateral orbit and can be confused for lacrimal gland tumors. They include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Epidermoid or dermoid cyst, commonly found at the frontozygomatic suture and may have an intraorbital component</p>
          </list-item>
          <list-item>
            <p>Prolapsed orbital fat, causing fullness of the lateral upper lid or a mass in the superotemporal fornix</p>
          </list-item>
          <list-item>
            <p>Dermatolipoma, commonly seen under the superotemporal conjunctiva</p>
          </list-item>
          <list-item>
            <p>Prolapsed lacrimal gland, giving the appearance that it has been displaced by a mass</p>
          </list-item>
        </list>
        <p>Lacrimal gland enlargement can also be seen in amyloidosis. Though rare, amyloid deposition in orbit, including the lacrimal gland, is usually due to a localized disease process rather than associated with systemic amyloidosis.<xref ref-type="bibr" rid="article-140265.r27">[27]</xref></p>
      </sec>
      <sec id="article-140265.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Due to their common embryologic origin, lacrimal gland tumors are classified similarly to salivary tumors as dictated by the World Health Organization's guidelines.<xref ref-type="bibr" rid="article-140265.r28">[28]</xref> Lacrimal gland tumor staging is&#x000a0;according&#x000a0;to the American Joint Committee on Cancer (AJCC), the eighth edition.<xref ref-type="bibr" rid="article-140265.r29">[29]</xref> Lacrimal gland lymphomas are staged similar to other ocular adnexal lymphomas as per the AJCC.<xref ref-type="bibr" rid="article-140265.r30">[30]</xref></p>
      </sec>
      <sec id="article-140265.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Since adenoid cystic carcinoma is the most common malignant tumor, it has the most prognostic data of the lacrimal gland carcinomas. Overall, the prognosis is poor,&#x000a0;and ACC&#x000a0;has often been referred to as the "slow killer" since recurrences and metastasis can occur years after treatment, with most patients dying within ten years of diagnosis.&#x000a0;Several prognostic factors have been identified in the literature, including tumor size, histologic subtype, perineural invasion, and the stage at diagnosis.<xref ref-type="bibr" rid="article-140265.r31">[31]</xref>&#x000a0;</p>
        <p>Tumor size is one of the more important factors, with a better prognosis for tumors that are less than 2.5 cm in greatest diameter.<xref ref-type="bibr" rid="article-140265.r24">[24]</xref>&#x000a0;Histologically, these&#x000a0;tumors typically have multiple subtypes, but the predominance of the cribriform (Swiss cheese) pattern may be a positive prognostic factor, whereas a predominance of "basaloid" or solid pattern may be a negative factor.<xref ref-type="bibr" rid="article-140265.r32">[32]</xref><xref ref-type="bibr" rid="article-140265.r33">[33]</xref><xref ref-type="bibr" rid="article-140265.r34">[34]</xref>&#x000a0; The AJCC TNM stage does reasonably well with predicting outcomes of patients, with a worse prognosis for recurrence, metastasis, and death for tumors less than stage T3a than for one wish stage T3a or greater.</p>
        <p>For carcinoma ex pleomorphic adenoma, the prognosis depends on the identity and behavior of the malignant component of the tumor that has spread beyond the capsule of the original tumor.&#x000a0;If the tumor is non- or minimally invasive, the prognosis is excellent.&#x000a0;Otherwise, most patients die within a few years due to intracranial spread and metastases to the lungs, chest, and bone.<xref ref-type="bibr" rid="article-140265.r3">[3]</xref><xref ref-type="bibr" rid="article-140265.r10">[10]</xref></p>
        <p>Mucoepidermoid carcinoma is organized into low, intermediate, and high-grade tumors. The low and intermediate tumors carry a good prognosis, but high-grade tumors have a poor survival rate.<xref ref-type="bibr" rid="article-140265.r3">[3]</xref></p>
        <p>Ductal carcinoma is an aggressive neoplasm that usually presents as locally advanced disease that is difficult to control, with a mortality rate of over 40%.&#x000a0;Metastases develop in more than 50% of cases.</p>
        <p>The prognosis for lymphoma overall is good, though it depends on the extent of systemic involvement. For extranodal marginal zone lymphoma localized to just the orbit is very good, as it is usually sensitive to radiation therapy. Diffuse large B cell lymphoma has three subtypes, with the ABC subtype having the poorest prognosis.<xref ref-type="bibr" rid="article-140265.r8">[8]</xref></p>
      </sec>
      <sec id="article-140265.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of malignant tumors are mostly related to the treatment involved in eradicating the tumor and preventing recurrences. The tumors may compress orbital structures like the globe or optic nerve if the tumors are large. Malignant lesions may erode through the orbital roof to gain access to the intracranial vault, or in the case of adenoid cystic carcinoma, may spread via the perineural route to access the CNS where severe neurologic changes may manifest.</p>
        <p>Surgical biopsy or excision carries risks, and complications are related to the surgery performed and the techniques utilized. For anterior or lateral orbitotomies, the main complications of note include orbital hemorrhage, postoperative orbital cellulitis, damage to the extraocular muscles, globe, or optic nerve, dryness from decreased lacrimal gland function, cerebral spinal fluid (CSF) leak, or recurrence of the tumor.</p>
        <p>Radiation therapy can also have adverse effects, including surrounding tissue damage, dermatitis of the skin, atrophy of the bone and soft tissues, and ocular effects, including retinopathy and dry eye disease. Chemotherapy can lead to many side effects, the most concerning being immunosuppression and the risk of infection. Vigilant short- and long-term monitoring after treatment is crucial to managing&#x000a0;these complications and monitoring for tumor recurrences.</p>
      </sec>
      <sec id="article-140265.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The management of malignant tumors in an area such as the orbit can be quite complicated. A thorough discussion is necessary to inform the patient of the potential causes, treatments, adverse events, and prognosis of both the disease processes involved and the treatment options. Whenever cancer is being discussed as a diagnosis, it is critical to approach the patient and situation with compassion and empathy. At times this may necessitate multiple discussions so the patient can process the information appropriately and make an informed decision.</p>
        <p>The risks, benefits, and alternatives of any treatment (or lack of treatment) should be thoroughly explained. The emotional and psychological impact of the diagnoses involved and the treatments (surgery, chemotherapy, radiation, long-term monitoring for recurrence, etc.) and especially any complications that arise may require multi-specialty attention from a primary care provider, oncologist, psychologist, or psychiatrist.</p>
      </sec>
      <sec id="article-140265.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>When evaluating any patient with an orbital mass, keeping a broad differential diagnosis is vital. A thorough history and clinical exam&#x000a0;are paramount for determining risk factors for various disease processes and guiding diagnostic workup and treatment acuity. Malignant lesions often carry a poor prognosis, and thus expedient workup and treatment are essential.</p>
        <p>Inflammatory signs are not often seen with tumors and may indicate infectious or inflammatory dacryoadenitis. Pain or hypoesthesia is often an indicator of malignancy as most benign lesions are painless. Imaging is equally important in diagnosis and the decision-making process for treatment; it can also aid with surgical planning. The treatment of malignant tumors requires a multi-specialty approach with physicians experienced in managing these orbital tumors and their complications.</p>
        <table-wrap id="article-140265.table0" position="float" orientation="portrait">
          <table style="height: 512px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Adenoid Cystic Carcinoma</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Orbital Lymphoma</td>
              </tr>
              <tr>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Age of onset</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Middle Age</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Older Adults</td>
              </tr>
              <tr>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Gender</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Male</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Female</td>
              </tr>
              <tr>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Associated Pain</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Yes</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">No</td>
              </tr>
              <tr>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Duration of onset</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Acute</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Indolent</td>
              </tr>
              <tr>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Histopathology</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">
<p>Various</p>
<p>Unencapsulated</p>
</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">
<p>Monoclonal sheet</p>
<p>Unencapsulated</p>
</td>
              </tr>
              <tr>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">Treatment</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">
<p>Combination Therapy</p>
<p>Excision/Radiation/Exenteration</p>
</td>
                <td style="width: 179px; text-align: center;" rowspan="1" colspan="1">
<p>Radiation (Local)</p>
<p>Chemotherapy (Systemic)</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-140265.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>From start to finish, the journey from clinical evaluation to work up, then diagnosis to management,&#x000a0;and&#x000a0;subsequent monitoring treatment response to managing complications requires a large,&#x000a0;interprofessional team of administrators, staff, technicians, nurses, and doctors. The treatments for malignant tumors often involve multiple surgeries, radiation treatments, chemotherapy infusions, and countless office visits. The patient will interact with dozens of individuals in the professional setting during their care. Effective communication between all parties is necessary to promote the efficient use of medical resources and provide a smooth and&#x000a0;effective experience for the patient. [Level&#x000a0;4]</p>
      </sec>
      <sec id="article-140265.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140265&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140265">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/lacrimal-gland-malignancies/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140265">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140265/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140265">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140265.s18">
        <fig id="article-140265.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Lacrimal Gland Malignancy. A 45-year-old patient with left eye proptosis and vision changes was found to have a left orbital mass. Post-contrast T1 MRI images show an avidly enhancing solid mass arising from the lacrimal gland fossa extending posteriorly towards the orbital apex, with surrounding erosion of the bone. A biopsy of the mass resulted in a diagnosis of adenoid cystic carcinoma. Contributed by A Mueller, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACC" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140265.s19">
        <fig id="article-140265.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Adenoid Cystic Carcinoma. The clinical photo showed abaxial proptosis on the left side with inferomedial globe dystopia in the left eye. MRI showed a well-defined mass in the lacrimal gland fossa that was hyperintense on T2 and hypointense on T1-weighted images. Histopathological analysis revealed adenoid cystic carcinoma of the lacrimal gland, one of the common lacrimal gland malignancies. Contributed by M Hada, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="adenoid__cystic" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140265.s20">
        <fig id="article-140265.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Lacrimal Gland Lymphoma, 25&#x000d7; View Contributed by H Grossniklaus, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="lac__gland__lymphoma__25X" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140265.s21">
        <fig id="article-140265.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Lacrimal Gland Adenoid Cystic Carcinoma 25&#x000d7; Contributed by H Grossniklaus, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="lac__gland__adenoid__cystic__carcinoma__25X" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140265.s22">
        <fig id="article-140265.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Lacrimal Gland Pleomorphic Adenoma 25&#x000d7; Contributed by H Grossniklaus, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="lac__gland__pleomorphic__adenoma__25X" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140265.s23">
        <title>References</title>
        <ref id="article-140265.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Scartozzi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Review: primary epithelial malignancies of the lacrimal gland: the 2003 Ramon L. Font lecture.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-21</page-range>
            <pub-id pub-id-type="pmid">14752304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Liss</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Masses of the Lacrimal Gland: Evaluation and Treatment.</article-title>
            <source>J Neurol Surg B Skull Base</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>100</fpage>
            <page-range>100-106</page-range>
            <pub-id pub-id-type="pmid">33777623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Holstein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Briscoe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Tourneau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2013</year>
            <month>May</month>
            <volume>91</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-206</page-range>
            <pub-id pub-id-type="pmid">22471335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Holstein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tumors of the lacrimal gland.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2016</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-63</page-range>
            <pub-id pub-id-type="pmid">26849904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Lacrimal gland tumors.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>1993</year>
            <season>Summer</season>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-8</page-range>
            <pub-id pub-id-type="pmid">8407184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernardini</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Devoto</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Croxatto</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Epithelial tumors of the lacrimal gland: an update.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>409</fpage>
            <page-range>409-13</page-range>
            <pub-id pub-id-type="pmid">18772674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Currie</surname>
                <given-names>ZI</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Long-term risk of recurrence after intact excision of pleomorphic adenomas of the lacrimal gland.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>125</volume>
            <issue>12</issue>
            <fpage>1643</fpage>
            <page-range>1643-6</page-range>
            <pub-id pub-id-type="pmid">18071115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreasen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Esmaeli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Holstein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An Update on Tumors of the Lacrimal Gland.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-172</page-range>
            <pub-id pub-id-type="pmid">28399336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasosah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baothman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Satti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kutbi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland: sustained remission after eradication of helicobacter pylori infection.</article-title>
            <source>Case Rep Gastrointest Med</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>945752</fpage>
            <pub-id pub-id-type="pmid">22606434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Proia</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Ranjit-Reeves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Lacrimal Gland Tumors.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2018</year>
            <season>Spring</season>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-235</page-range>
            <pub-id pub-id-type="pmid">29517651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasmussen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ralfkiaer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prause</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Siersma</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Malignant lymphoma of the lacrimal gland: a nation-based study.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>129</volume>
            <issue>10</issue>
            <fpage>1275</fpage>
            <page-range>1275-80</page-range>
            <pub-id pub-id-type="pmid">21987669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreasen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grauslund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2017</year>
            <month>May</month>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-306</page-range>
            <pub-id pub-id-type="pmid">27808478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Von Holstein</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Fehr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Therkildsen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>CRTC1-MAML2 gene fusion in mucoepidermoid carcinoma of the lacrimal gland.</article-title>
            <source>Oncol Rep</source>
            <year>2012</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>1413</fpage>
            <page-range>1413-6</page-range>
            <pub-id pub-id-type="pmid">22323114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Pushker</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghose</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic review of epithelial tumors of the lacrimal gland.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>440</fpage>
            <page-range>440-5</page-range>
            <pub-id pub-id-type="pmid">24145905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>The radiological spectrum of orbital pathologies that involve the lacrimal gland and the lacrimal fossa.</article-title>
            <source>Korean J Radiol</source>
            <year>2007</year>
            <season>Jul-Aug</season>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>336</fpage>
            <page-range>336-42</page-range>
            <pub-id pub-id-type="pmid">17673845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaidhyanath</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kirke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sampath</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Lacrimal fossa lesions: pictorial review of CT and MRI features.</article-title>
            <source>Orbit</source>
            <year>2008</year>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>410</fpage>
            <page-range>410-8</page-range>
            <pub-id pub-id-type="pmid">19085295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenzano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>The "Wedge Sign": An Imaging Sign for Aggressive Lacrimal Gland Disease.</article-title>
            <source>Ophthalmology</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>124</volume>
            <issue>7</issue>
            <fpage>1081</fpage>
            <page-range>1081-1083</page-range>
            <pub-id pub-id-type="pmid">28372859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;nd&#x000fc;z</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Ye&#x0015f;ilta&#x0015f;</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Overview of benign and malignant lacrimal gland tumors.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>458</fpage>
            <page-range>458-468</page-range>
            <pub-id pub-id-type="pmid">30028745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>08</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <pub-id pub-id-type="pmid">31176360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Yeom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Esmaeli</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Management of Lacrimal Gland Carcinoma: Lessons From the Literature in the Past 40 Years.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">26291539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonavolont&#x000e0;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Esmaeli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Donna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tranfa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iuliano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abbate</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fossataro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Attanasi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonavolont&#x000e0;</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Outcomes after eye-sparing surgery vs orbital exenteration in patients with lacrimal gland carcinoma.</article-title>
            <source>Head Neck</source>
            <year>2020</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>988</fpage>
            <page-range>988-993</page-range>
            <pub-id pub-id-type="pmid">32048377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Sobti</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Outcomes of Eye-Sparing Surgery for Adenoid Cystic Carcinoma of Lacrimal Gland.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2018</year>
            <season>Jan/Feb</season>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-78</page-range>
            <pub-id pub-id-type="pmid">28221296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tse</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Kossler</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Benedetto</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>120</volume>
            <issue>7</issue>
            <fpage>1313</fpage>
            <page-range>1313-23</page-range>
            <pub-id pub-id-type="pmid">23582989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woo</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Sa</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Esmaeli</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Current treatment of lacrimal gland carcinoma.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>449</fpage>
            <page-range>449-56</page-range>
            <pub-id pub-id-type="pmid">27273588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Debnam</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Esmaeli</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Malignant Mixed Tumor (Carcinoma Ex Pleomorphic Adenoma) of the Lacrimal Gland.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2020</year>
            <season>Sep/Oct</season>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>497</fpage>
            <page-range>497-502</page-range>
            <pub-id pub-id-type="pmid">32282452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Freire</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Komarnicky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Plaque radiotherapy for selected orbital malignancies: preliminary observations: the 2002 Montgomery Lecture, part 2.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-5</page-range>
            <pub-id pub-id-type="pmid">12644752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Vemuganti</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Lacrimal gland amyloidosis: a clinicopathological correlation of a rare disorder and review of literature.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>300</fpage>
            <page-range>300-5</page-range>
            <pub-id pub-id-type="pmid">24205967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2375</fpage>
            <page-range>2375-90</page-range>
            <pub-id pub-id-type="pmid">26980727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Changes in the 7th edition of the AJCC TNM classification and recommendations for pathologic analysis of lacrimal gland tumors.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>133</volume>
            <issue>8</issue>
            <fpage>1268</fpage>
            <page-range>1268-71</page-range>
            <pub-id pub-id-type="pmid">19653723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Damato</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Finger</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>A TNM-based clinical staging system of ocular adnexal lymphomas.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>133</volume>
            <issue>8</issue>
            <fpage>1262</fpage>
            <page-range>1262-7</page-range>
            <pub-id pub-id-type="pmid">19653722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Esmaeli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Woog</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Selvadurai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Selva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McNab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Calle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>American Joint Committee on Cancer classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma.</article-title>
            <source>Ophthalmology</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>1210</fpage>
            <page-range>1210-5</page-range>
            <pub-id pub-id-type="pmid">19395039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Ilstrup</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland.</article-title>
            <source>Ophthalmology</source>
            <year>1985</year>
            <month>Jan</month>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-34</page-range>
            <pub-id pub-id-type="pmid">2983279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Berean</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Al-Katan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bonavolont&#x000e0;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Strianese</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Vangveeravong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lapointe</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Epithelial lacrimal gland tumors: pathologic classification and current understanding.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>127</volume>
            <issue>8</issue>
            <fpage>1016</fpage>
            <page-range>1016-28</page-range>
            <pub-id pub-id-type="pmid">19667339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140265.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gamel</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Font</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern.</article-title>
            <source>Hum Pathol</source>
            <year>1982</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-25</page-range>
            <pub-id pub-id-type="pmid">6281163</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
